All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Sulfonamides, or SULFA drugs, were the first chemical substances systematically used to treat and prevent bacterial infections \[[@ppat.1005949.ref001], [@ppat.1005949.ref002]\], but the use of these drugs gradually declined because of the emergence of resistant organisms \[[@ppat.1005949.ref003]\]. To increase SULFAs' potency and prevent further resistance, trimethoprim (TMP), which provides synergy, was later developed \[[@ppat.1005949.ref004]\]. Combination regimens using TMP and SULFAs have effectively treated acute urinary tract infections, bacterial meningitis, *Pneumocystis jiroveci* pneumonia, and shigellosis, and are commonly used as prophylaxis against recurrent and drug resistant infections \[[@ppat.1005949.ref003], [@ppat.1005949.ref005], [@ppat.1005949.ref006]\]. Unfortunately, TMP has been the only SULFA booster approved for clinical use, and resistance to both TMP and SULFAs has emerged \[[@ppat.1005949.ref007]\]. In addition, the synergistic effect of TMP remains questionable in many bacteria, including *Mycobacterium tuberculosis* and *Pseudomonas aeruginosa* \[[@ppat.1005949.ref008], [@ppat.1005949.ref009]\]. To protect the efficacy of SULFAs and safely expand their clinical use \[[@ppat.1005949.ref010]\], novel SULFA boosters are required. A recent strategy for developing antibiotic boosters is "resisting resistance" \[[@ppat.1005949.ref011]\], in which inhibitors that suppress resistance mechanisms are used to sensitize host bacteria to antibiotics. Our laboratory recently suggested that targeting antifolate resistance may lead to the development of such adjunctive chemotherapies for SULFAs and TMP \[[@ppat.1005949.ref012]\]. We found that disruption of 5,10-methenyltetrahydrofolate synthase (MTHFS), an enzyme responsible for the conversion of *N* ^5^-formyltetrahydrofolate (5-CHO-H~4~PteGlu~n~) to *N* ^5^,*N* ^10^-methenyltetrahydrofolate (5,10-CH^+^-H~4~PteGlu~n~) in the folate-dependent one-carbon metabolic network ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}), led to severe defects in cellular folate homeostasis thus weakening the intrinsic antifolate resistance in bacteria \[[@ppat.1005949.ref012]\].

![Chemo-genomic characterization of antifolate resistance determinants in *M*. *smegmatis*.\
(**A**) Simplified enzymatic conversions of folate derivatives in *de novo* biosynthesis and the one-carbon metabolic network in bacteria. Abbreviations: H~4~PteGlu~n~, tetrahydrofolate (green) serves as carrier for one-carbon groups. AICART, aminoimidazolecarboxamide ribonucleotide transferase; DHFS, dihydrofolate synthase; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; FTD, 10-formyltetrahydrofolate dehydrogenase; FTS, 10-formyltetrahydrofolate synthetase; Gly, glycine; GTP, guanosine triphosphate; H~2~PteGlu~n~, dihydrofolate; Hcy, homocysteine; Met, methionine; MS, methionine synthase; MTCH, methylenetetrahydrofolate cyclohydrolase; MTD, methylenetetrahydrofolate dehydrogenase; MTHFR, methylenetetrahydrofolate reductase; MTHFS, 5,10-methenyltetrahydrofolate synthetase; pABA, para-aminobenzoic acid; PGT, phosphoribosyl glycinamide transferase; Pte, pteroate; PteGlu~1~, folic acid; Ser, serine; SHMT, serine hydroxymethyltransferase; TS, thymidylate synthase. Two different types of TS have been described: ThyA and ThyX. While most organisms contain either ThyA or ThyX, some organisms including *M*. *tuberculosis* have both. Reactions directly involved in the methylfolate trap (MS) and thymineless death (TS) are highlighted in yellow and red, respectively. (**B**) Genome distributions of antifolate resistance determinants in *M*. *smegmatis*. Laboratory assigned catalog numbers (n = 1--50, [S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}) were plotted against their corresponding locus tags (*msmeg\_*No.). (**C**) A typical SULFA susceptibility and chemical complementation assay of *M*. *smegmatis* strains. A pool of antifolate sensitive mutants was replicated onto NE plates, in top-down order: (*i*) control, (*ii*) SCP, (*iii*) SCP plus PteGlu~1~, (*iv*) SCP plus 5-CHO-H~4~PteGlu~1~, (*v*) SCP plus 5-CH~3~-H~4~PteGlu~1~, and (*vi*) SCP plus pABA. SCP was used at 10.5 μg/ml while supplements were used at 0.3 mM final concentration. Colonies marked with "C" were from the parental strain mc^2^155, which was used as a control. Colonies marked with asterisks were from the "white" mutants.](ppat.1005949.g001){#ppat.1005949.g001}

TMP and SULFAs are bacteriostatic in minimal media. However, they become more bactericidal in rich media, particularly when cellular levels of glycine, methionine and purines are high. In such conditions, the multifactorial deficiency caused by SULFAs is reduced to a single deficiency of thymine ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}, highlighted in red), and cells undergoing such "unbalanced growth" succumb to thymineless death \[[@ppat.1005949.ref013]--[@ppat.1005949.ref017]\]. Exogenous thymine supplementation reduces the bactericidal activity of SULFAs and TMP \[[@ppat.1005949.ref014], [@ppat.1005949.ref015]\]. Classified as folate antagonists, or antifolates, these drugs inhibit bacterial *de novo* folate biosynthesis ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}), which is absent in mammalian cells. While SULFAs target dihydropteroate synthase (DHPS), TMP inhibits dihydrofolate reductase (DHFR). Both of these enzymes are required for the formation of folate, a vitamin essential for cell growth across all kingdoms of life. The dominant form of folate in the cell is tetrahydrofolate (H~4~PteGlu~n~, with n indicating the number of glutamate moieties). This reduced folate molecule functions as a carrier of one-carbon units in multiple metabolic reactions that are required for the production of purines, thymidine, amino acids, and the recycling of homocysteine (Hcy), a non-protein amino acid harmful to long half-life proteins ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}) \[[@ppat.1005949.ref018]\].

Antifolate-mediated folate deficiency affects the biosynthesis of nucleic acids and proteins, as well as other important cellular processes including methylation and homeostasis of Hcy \[[@ppat.1005949.ref018]\]. In humans, defects in Hcy homeostasis, or hyperhomocysteinemia, are often associated with folate and vitamin B~12~ deficiencies observed in medical conditions such as anemia, neural tube defects, cardiovascular diseases, Alzheimer's dementia, stroke, cancers, and others \[[@ppat.1005949.ref018]\]. This interconnected metabolic syndrome has been explained by the "methylfolate trap" hypothesis that assigns its cause to defects in the multi-cycling reaction catalyzed by the B~12~-dependent methionine synthase (MetH, EC:2.1.1.13) ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}, highlighted in yellow) \[[@ppat.1005949.ref019]--[@ppat.1005949.ref021]\]. This reaction depends on three components: (*i*) *N* ^5^-methyltetrahydrofolate (5-CH~3~-H~4~PteGlu~n~), a methyl donor, (*ii*) B~12~, the intermediate carrier for the methyl group, and (*iii*) the catalytic activity provided by MetH. Besides the methylation of Hcy to form methionine, this reaction recycles 5-CH~3~-H~4~PteGlu~n~ back to free H~4~PteGlu~n~ which can be further converted to other folate forms ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}) \[[@ppat.1005949.ref020], [@ppat.1005949.ref021]\]. This reaction can be compromised by B~12~ deficiency and/or mutations affecting MetH enzymatic activity. Consequently, the cellular pool of H~4~PteGlu~n~ is trapped in the methylated form (5-CH~3~-H~4~PteGlu~n~), thus interrupting the normal flow of the one-carbon metabolic network ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}) \[[@ppat.1005949.ref021]--[@ppat.1005949.ref024]\]. 5-CH~3~-H~4~PteGlu~n~ is generated from *N* ^5^,*N* ^10^-methylenetetrahydrofolate (5,10-CH~2~-H~4~PteGlu~n~) in an upstream reaction catalyzed by methylenetetrahydrofolate reductase (MTHFR), which is irreversible *in vivo* \[[@ppat.1005949.ref025]\] and suppressed by *S*-adenosylmethionine (SAM) \[[@ppat.1005949.ref026]\]. Since SAM is produced from methionine, inhibition of MetH activity leads to reduced SAM levels, thus resulting in derepression of MTHFR, further accelerating the accumulation of 5-CH~3~-H~4~PteGlu~n~ and Hcy \[[@ppat.1005949.ref026]\]. Attempts to delete *metH* in mice were unsuccessful as homozygous knockout embryos all died following implantation \[[@ppat.1005949.ref027]\]. Although it has been studied in humans, and *ex vivo* in mammalian cells, the existence or physiological significance of the methylfolate trap in bacteria has never been documented.

Here we report the identification of the methylfolate trap as a novel determinant of SULFA resistance in bacteria. Upon its formation in response to SULFAs, the methylfolate trap causes impaired homeostasis of folate and related metabolites, including a progressive accumulation of Hcy-thiolactone that is known to be cytotoxic. More importantly, cells undergoing the methylfolate trap are also unable to deplete glycine and nucleotides, and suffer thymineless death induced by SULFAs. This metabolic blockage renders pathogenic bacteria, including *M*. *tuberculosis*, *P*. *aeruginosa*, *Escherichia coli* and *Salmonella typhimurium* more susceptible to existing SULFAs both *in vitro* and in host macrophages. Furthermore, chemical induction of the methylfolate trap, as shown in our experiments, represents a viable method for boosting the antimicrobial activity of available, clinically approved SULFAs against bacterial pathogens.

Results {#sec002}
=======

Genome-wide characterization of antifolate resistance in *M*. *smegmatis* {#sec003}
-------------------------------------------------------------------------

A screen of 13,500 *Himar1*-transposon *M*. *smegmatis* mutants (details can be found in Supplemental [S1 Text](#ppat.1005949.s016){ref-type="supplementary-material"}) identified a collection of strains that displayed normal growth in the absence of antifolates but suffered defects in antifolate resistance. After 2 rounds of drug susceptibility tests, the disrupted genes were mapped using nested PCRs, followed by sequencing. Of the 50 chromosomal loci identified as being responsible for the intrinsic antifolate resistance of *M*. *smegmatis* ([S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}), 31 genes (62%) encoded enzymatic activities, 14 of which (28%) were predicted to be involved in folate metabolism or related pathways. The identification of many genes whose functions are related to folate metabolism indicated that the screen was successful. Overall, the resistance determinants were evenly distributed throughout the *M*. *smegmatis* genome with some relatively discrete regions and gaps ([Fig 1B](#ppat.1005949.g001){ref-type="fig"}).

Besides many genes encoding homologs of enzymes of the one-carbon metabolic network and related metabolism of amino acids or nucleotides (*fmt*, *dcd*, *gabD*, *cobIJ*, *metH*, *glyA*, *ygfA*, and *ygfZ*), genetic mapping revealed *Himar1* insertions in genes that encode proteins previously known to provide non-specific antibiotic resistance (*pknG*, *mshB*, *cspB*, *fbpA*, and *treS*) \[[@ppat.1005949.ref028]--[@ppat.1005949.ref033]\] ([S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}). In addition, insertions were mapped to chromosomal loci potentially affecting regulatory or signaling processes (*mprA*, *sigB*, *sigE*, *pknG*, *pafA*, *pup*, *pcrB*, and *pcrA*), transsulfuration (*cysH* and *mshB*), transport (*mmpL* and *pstC*), and other cellular activities ([S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}).

Mutants were further profiled using chemical complementation. Para-aminobenzoic acid (pABA) or a folate derivative ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}, blue rectangles, & [Fig 1C](#ppat.1005949.g001){ref-type="fig"}) was added exogenously to support growth in the presence of SULFAs or TMP, which inhibit *de novo* folate synthesis. These analyses provided useful geno-chemo-phenotypic information to each individual antifolate resistance determinant ([S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}).

Methylfolate trap as a SULFA resistance determinant in *M*. *smegmatis* {#sec004}
-----------------------------------------------------------------------

Chemical complementation identified a group of SULFA-sensitive, "white" mutants that lost the yellow pigment typically displayed by *M*. *smegmatis* ([Fig 1C](#ppat.1005949.g001){ref-type="fig"}, marked with asterisks). The mutants were unable to use exogenous 5-CH~3~-H~4~PteGlu~1~ to antagonize SULFAs ([Fig 1C](#ppat.1005949.g001){ref-type="fig"}, panel (*v*)). Genetic mapping showed that four mutants in this subgroup had *Himar1* insertions at three different TA dinucleotides within the same gene, *msmeg_4185* (2xTA^499-500^, 1xTA^2881-2882^, and 1xTA^3091-3092^, [S1 Fig](#ppat.1005949.s001){ref-type="supplementary-material"}), which encodes a homolog of B~12~-dependent methionine synthase. Two other mutants had insertions at TA^112-113^ of *msmeg_3873*, which encodes an enzyme (CobIJ) that catalyzes two methylation steps, precorrin-2 C20 methyltransferase \[CobI, EC:2.1.1.130\] and precorrin-3B C17-methyltransferase \[CobJ, EC:2.1.1.131\], of the B~12~ (cobalamin) biosynthetic pathway. Interestingly, the function of these 5-CH~3~-H~4~PteGlu~n~-related genes were reminiscent of factors involved in the methylfolate trap, a metabolic disorder thus far only described in mammalian cells ([Fig 2A](#ppat.1005949.g002){ref-type="fig"}). Whereas the *metH*-encoded enzyme catalyzes the reaction, *cobIJ* is required for the *de novo* biosynthesis of B~12~, the cofactor required for MetH activity.

![Methylfolate trap in *Mycobacterium smegmatis*.\
(**A**) A model depicting the chemical conversions and factors involved in the methylfolate trap-mediated SULFA sensitivity. The CH~3~- group in 5-CH~3~-H~4~PteGlu~n~ is first transferred to the B~12~ cofactor, which further transfers it to homocysteine (Hcy) to make methionine (Met). The MetH reaction thereby recycles 5-CH~3~-H~4~PteGlu~n~ back to free H~4~PteGlu~n~ which continues the flow of the one-carbon network. (**B**) Chemical complementation of *M*. *smegmatis* "white" mutants mapped to *metH* or *cobIJ*. The strains exhibited increased SULFA susceptibility and impaired 5-CH~3~-H~4~PteGlu~1~ utilization. Approximately 5x10^3^ cells were spotted onto NE medium added with 10.5 μg/ml SCP with or without exogenous supplements. Unlike wild type and other mutants, these mutants were unable to use 5-CH~3~-H~4~PteGlu~1~ to antagonize SCP. Exogenous B~12~ restored 5-CH~3~-H~4~PteGlu~1~ utilization and SCP resistance to *cobIJ* but not *metH* mutants. (**C**) Effect of *metH* and *cobIJ* on the folate pool in *M*. *smegmatis*. Growing cultures of *M*. *smegmatis* strains were treated with 285 μg/ml SCP for 30 min followed by folate extraction and LC-MS/MS analysis. Data shows the combined levels of all 5-CH~3~-H~4~PteGlu~n~ species (top), all non-methyl folate species (middle), and the total folate (bottom). Bars represent means of biological triplicates with standard deviations. P values are shown above the bars and were calculated using unpaired Student's t-test; ns, no significant difference between the indicated strains. (**D**) Targeted mutagenesis confirms the roles of *metH* and *cobIJ* in methylfolate trap-induced SULFA sensitivity and 5-CH~3~-H~4~PteGlu~1~ utilization in *M*. *smegmatis*. Paper discs were embedded with 0.5 mg SCP and placed at the center of the medium surface, seeded with bacterial strains. Exogenous B~12~ and 5-CH~3~-H~4~PteGlu~n~ were used at 0.3 and 1 mM, respectively. Genetic complementation was achieved by *in trans* expression of *metH* or *cobIJ*. B~12~ alone restored wild type SULFA resistance level to *Ms*Δ*cobIJ*, whereas the combination of 5-CH~3~-H~4~PteGlu~1~ and B~12~ completely abolished SULFA resistance to all strains but *Ms*Δ*metH*.](ppat.1005949.g002){#ppat.1005949.g002}

Exogenous B~12~ restored both SULFA resistance and 5-CH~3~-H~4~PteGlu~1~ utilization to *cobIJ*, but failed to restore the *metH* strains ([Fig 2B](#ppat.1005949.g002){ref-type="fig"}), resembling the "pseudo-folate deficiency" phenomenon previously observed in anemia patients (described in the Discussion) \[[@ppat.1005949.ref019]\]. To detect the methylfolate trap at a metabolic level, *M*. *smegmatis* strains growing in a liquid medium were challenged with sulfachloropyridazine (SCP) for half an hour to starve the cells from newly synthesized folate. Cultures were immediately harvested and total folate was extracted in subdued light. Samples added with internal standards were analyzed by LC-MS/MS as previously described \[[@ppat.1005949.ref012]\]. Both *metH* and *cobIJ* exhibited 5-CH~3~-H~4~PteGlu~n~ accumulation compared to wild type *M*. *smegmatis* ([Fig 2C](#ppat.1005949.g002){ref-type="fig"}). Exogenous B~12~ significantly reduced 5-CH~3~-H~4~PteGlu~n~ accumulation in the *cobIJ* mutant, though not to the level of wild type ([Fig 2C](#ppat.1005949.g002){ref-type="fig"}). This B~12~-responsive alteration in the cellular folate pool of *cobIJ* explained its pseudo-folate deficiency-like behavior in susceptibility tests ([Fig 2B](#ppat.1005949.g002){ref-type="fig"}). In the *cobIJ* mutant, the *metH* gene remained intact but its encoded protein did not have enough B~12~, due to the *Himar1* insertion into *cobIJ* disrupting *de novo* B~12~ biosynthesis, to activate its methionine synthase activity. When B~12~ was exogenously supplemented, the cofactor activated MetH activity, thus bypassing the B~12~ synthetic defect allowing for the release of the methylfolate trap.

To confirm that MetH and CobIJ contribute to the intrinsic SULFA resistance, and 5-CH~3~-H~4~PteGlu~n~ metabolism, the encoding genes, *msmeg_4185* and *msmeg_3873*, respectively, were individually deleted by homologous recombination \[[@ppat.1005949.ref034]\]. Similar to the transposon mutants, the targeted null mutants, *Ms*Δ*metH* and *Ms*Δ*cobIJ*, displayed increased SULFA susceptibility and impaired utilization of exogenous 5-CH~3~-H~4~PteGlu~1~ whereas *in trans* expression of *metH* and *cobIJ*, respectively, restored both phenotypes ([Table 1](#ppat.1005949.t001){ref-type="table"}, [Fig 2D](#ppat.1005949.g002){ref-type="fig"}). Exogenous B~12~ restored both SULFA resistance and 5-CH~3~-H~4~PteGlu~1~ utilization to *Ms*Δ*cobIJ*, but failed to do so for *Ms*Δ*metH*. Although the mutants were hypersusceptible to all SULFAs tested ([S2 Fig](#ppat.1005949.s002){ref-type="supplementary-material"}), resistance to non-antifolate antibiotics remained unaffected ([S3 Fig](#ppat.1005949.s003){ref-type="supplementary-material"}). While *M*. *smegmatis* encodes a B~12~-independent methionine synthase (MetE, EC: 2.1.1.14) \[[@ppat.1005949.ref035]\], deletion of *metE* did not affect SULFA sensitivity ([S4 Fig](#ppat.1005949.s004){ref-type="supplementary-material"} and [S5 Fig](#ppat.1005949.s005){ref-type="supplementary-material"}). These observations confirmed that MetH is essential for normal 5-CH~3~-H~4~PteGlu~n~ metabolism, which is required for the intrinsic SULFA resistance in *M*. *smegmatis*.

10.1371/journal.ppat.1005949.t001

###### Susceptibility of bacterial strains to antifolates.

![](ppat.1005949.t001){#ppat.1005949.t001g}

  MIC (μg/ml) [^a^](#t001fn002){ref-type="table-fn"}                 SMZ     TMP                                         SMZ/TMP [^b^](#t001fn003){ref-type="table-fn"}
  ------------------------------------------------------------------ ------- ------------------------------------------- ------------------------------------------------
  *P*. *aeruginosa*                                                  800     250                                         712.5/37.5
      *Pa*.*metH*                                                    80      30                                          47.5/2.5
      *Pa*.*btuB*                                                    70      30                                          38/2
      *Pa*.*cobI*                                                    135     30                                          57/3
      *Pa*.*cobJ*                                                    135     30                                          57/3
      *Pa*.*cobH*                                                    135     30                                          57/3
  *E*. *coli*                                                        255     0.375                                       2.85/0.15
      *Ec*Δ*metH*                                                    30      0.325                                       2.85/0.15
      *Ec*Δ*btuB*                                                    30      0.325                                       2.85/0.15
      *Ec*Δ*btuCED*                                                  255     0.375                                       2.85/0.15
      *Ec*Δ*btuCED*Δ*btuB*                                           30      0.375                                       2.85/0.15
  *S*. *typhimurium*                                                 385     0.1                                         1.425/0.075
      *St*.*metE*                                                    385     0.1                                         1.425/0.075
      *St*.*metE metH*                                               55      0.1                                         1.425/0.075
      *St*.*metE btuB*                                               35      0.1                                         1.425/0.075
      *St*.*metE cobI cobJ*                                          385     0.1                                         1.425/0.075
      *St*.*metE cobI cobJ btuB*                                     35      0.1                                         1.425/0.075
      *St*.*metE cobI*                                               385     0.1                                         1.425/0.075
  *M*. *smegmatis*                                                   1       ND [^e^](#t001fn006){ref-type="table-fn"}   ND
      *Ms*Δ*metH*                                                    0.125   ND                                          ND
      *Ms*Δ*metH*/*metH*                                             2       ND                                          ND
      *Ms*Δ*cobIJ*                                                   0.125   ND                                          ND
      *Ms*Δ*cobIJ*/*cobIJ*                                           1       ND                                          ND
      *Ms*.*metH*                                                    0.125   ND                                          ND
      *Ms*.*cobIJ*                                                   0.125   ND                                          ND
  *M*. *tuberculosis* H37Rv [^c^](#t001fn004){ref-type="table-fn"}   25      ND                                          ND
      RvΔ*metH*                                                      0.1     ND                                          ND
      RvΔ*metH* [^d^](#t001fn005){ref-type="table-fn"}               1       ND                                          ND
      RvΔ*metH*/*metH*                                               25      ND                                          ND
      RvΔ*cobIJ*                                                     25      ND                                          ND

Luria Broth was used for Gram-negative bacteria; 7H9-S and Dubos were used for *M*. *tuberculosis* and *M*. *smegmatis*, respectively.

^a^ Abbreviations: MIC, minimal inhibitory concentration, defined as the lowest concentration of an antibiotic that inhibits the visible growth of bacteria; *Pa*, *Pseudomonas aeruginosa*; *Ec*, *Escherichia coli*; *St*, *Salmonella typhimurium*; *Ms*, *Mycobacterium smegmatis*; *Mtb*, *Mycobacterium tuberculosis*; SMZ, sulfamethoxazole. TMP, trimethoprim.

^b^ SMZ/TMP used at ratio 19/1.

^c^ MIC tests for *M*. *tuberculosis* were performed in the presence of 0.3 mM B~12~.

^d^ Methionine was added at 1 mM concentration.

^e^ Not determined.

Methylfolate trap in *M*. *tuberculosis* {#sec005}
----------------------------------------

Mutants lacking *metH* or *cobIJ* genes were first constructed from the *M*. *tuberculosis* laboratory strain H37Rv (see [S1 Text](#ppat.1005949.s016){ref-type="supplementary-material"}). Sensitivity tests using the MTT method were performed with two minimal media, 7H9-S or Dubos, in the absence or presence of exogenous B~12~ (tested range: 1 μM---0.3 mM). In the absence of B~12~, SULFA susceptibility of the H37Rv-derived strains were similar. However, with B~12~ supplementation, significant differences in SULFA resistance among strains were observed ([Table 1](#ppat.1005949.t001){ref-type="table"}, [Fig 3A](#ppat.1005949.g003){ref-type="fig"}). While RvΔ*metH* displayed high susceptibility to sulfamethoxazole (SMZ), the sensitivity level of RvΔ*cobIJ* was unchanged compared to wild type ([Table 1](#ppat.1005949.t001){ref-type="table"}, [Fig 3A](#ppat.1005949.g003){ref-type="fig"}). *In trans* expression of *metH* completely restored wild type SULFA resistance to RvΔ*metH* ([Table 1](#ppat.1005949.t001){ref-type="table"}, [Fig 3A](#ppat.1005949.g003){ref-type="fig"}). These results indicated that the methylfolate trap was able to sensitize *M*. *tuberculosis* H37Rv to SULFA drugs. Such trap formation, however, requires the absence of methionine synthase activities.

![Methylfolate trap in *Mycobacterium tuberculosis*.\
(**A**) SULFA sensitivity of H37Rv-derived strains in 7H9-S medium, in the absence or presence of exogenous B~12~ and/or methionine (Met), was analyzed using the MTT method. Cultures grown to an OD~600~ of 2 were washed and diluted in 7H9-S. Wells were inoculated with 10^4^ cells in the presence of 1.56 μg/ml SMZ supplemented with 0.3 mM B~12~ alone and in combination with 1 mM methionine. Plates were incubated for 7 days at 37°C. MTT solution prepared in 1X PBS, pH 6.8, was added to each well and incubated for 24 hours. The reaction was stopped by adding SDS-DMF solution followed by incubation at 37°C for an additional 24 hours. Purple formazan indicates living cells. (**B**) H37Rv-derived strains were grown to OD~600~ of 1 and 5 μl cultures were spotted onto 7H10-OADC or the same medium supplemented with 5.7 μg/ml SCP, 0.5 mM B~12~, and 1 mM methionine. Plates were incubated at 37°C for 4 weeks. The spotted cell suspension for each strain under both conditions was collected and suspended in 7H9-OADC. Suspensions underwent 10-fold serial dilutions from which 100 μl aliquots were plated onto 7H10-OADC in triplicate. After 4 weeks of incubation at 37°C, viability was determined by counting colony forming unit (c.f.u.) and normalized to the c.f.u. values of the input inoculum. The y-axis represents c.f.u. fold-change on a log10 scale. Bars represent standard deviations from experimental triplicates. P values are shown above the bars and were calculated using unpaired Student's t-test; ns, no significant difference compared to corresponding H37Rv sample in same condition. Representative 10^−6^ dilution plates provide a visual comparison between strains in viability (top). (**C**) Domain alignment of MetH proteins from H37Rv and CDC1551 using PROSITE ([http://prosite.expasy.org](http://prosite.expasy.org/)). Domains are labeled as the cofactors to which they bind. (**D**) SULFA sensitivity of CDC1551-derived strains in Dubos medium in the absence or presence of B~12~ and methionine was analyzed using the MTT method. Cultures growing at an OD~600~ of 2 were washed and diluted in Dubos medium. Wells containing two-fold increasing SMZ concentrations (0--8 μg/ml) were inoculated with 10^4^ cells of each strain, as indicated in the box on the left. Test plates, supplemented with varying concentrations of B~12~ (0.25--1 μM), without or with 1 mM methionine, were incubated for 7 days at 37°C. MTT solution was added to each well and incubated for 24 hours. The reaction was stopped by adding SDS-DMF solution followed by incubation at 37°C for an additional 24 hours. Purple formazan indicates living cells. (**E**) Survival of H37Rv (Red), its derived *metH* mutant (RvΔ*metH*, Blue) and the complemented strain (RvΔ*metH*/*metH*, Green) in macrophages, non-treated or treated with 40 μg/ml SMZ. Presented data are the c.f.u. values of internalized bacteria at 0 h (0) and after 72 h chase without (-) or with (+) 40 μg/ml SMZ. Shown are means of biological triplicates with standard deviations. \*\* p\<0.01; ns, no significant difference compared to corresponding H37Rv sample. The data presented is the representative of four independent experiments. (**F**) Survival of H37Rv (Red), CDC1551 (Blue), and the CDC1551 strain *in trans* expressing the intact *metH* gene from H37Rv (CDC1551/*metH*, Green) in macrophages, non-treated or treated with 40 μg/ml SMZ. Presented data are the c.f.u. values of internalized bacteria at 0 h (0) and after 72 h chase without (-) or with (+) 40 μg/ml SMZ. Shown are means of biological triplicates with standard deviations. \*\* p\<0.01; ns, no significant difference compared to H37Rv.](ppat.1005949.g003){#ppat.1005949.g003}

In agreement with previous studies \[[@ppat.1005949.ref036], [@ppat.1005949.ref037]\], our data suggested that H37Rv is unable to synthesize B~12~ *de novo*, and that this organism relies on its uptake system for obtaining B~12~ from the environment. In the complete absence of B~12~, H37Rv employed the B~12~-independent methionine synthase MetE to prevent the methylfolate trap. When B~12~ was added exogenously, MetE activity was inhibited, making RvΔ*metH* completely null of methionine synthases. In such a condition, the methylfolate trap was formed sensitizing RvΔ*metH* to SULFA drugs. It is important to note that exogenous supplementation of methionine only partially enhanced SMZ resistance of RvΔ*metH* ([Table 1](#ppat.1005949.t001){ref-type="table"}), indicating that the lack of methionine due to defective methionine synthases \[[@ppat.1005949.ref037], [@ppat.1005949.ref038]\] is not the sole contributor to the enhanced SULFA susceptibility. To further characterize the methionine-unrelated methylfolate trap-mediated SULFA sensitivity, survival of the *M*. *tuberculosis* strains treated with SMZ, B~12~, and methionine were assayed by serial dilution and colony forming unit (c.f.u.) counting. With similar inputs, the survival of RvΔ*metH* was 3 log10 lower than that of wild type *M*. *tuberculosis* H37Rv and the RvΔ*cobIJ* mutant ([Fig 3B](#ppat.1005949.g003){ref-type="fig"}). This result not only confirmed our observation from the growth inhibition assays ([Table 1](#ppat.1005949.t001){ref-type="table"}, [Fig 3A](#ppat.1005949.g003){ref-type="fig"}), but further suggested that the methylfolate trap may induce the intrinsic bactericidal activity of SULFA drugs.

To further characterize the methylfolate trap in *M*. *tuberculosis*, we used CDC1551, a clinical strain isolated in a 1994--1996 tuberculosis outbreak in the United States \[[@ppat.1005949.ref039]\], for constructing several strains related to methylfolate trap formation ([S2 Table](#ppat.1005949.s013){ref-type="supplementary-material"}). CDC1551 is a natural *metH* deletion mutant due to a 1,196-bp truncation located at the 3'-terminus of its encoding gene (*mt2183*) ([Fig 3C](#ppat.1005949.g003){ref-type="fig"}) \[[@ppat.1005949.ref038], [@ppat.1005949.ref040]\]. Similar to the *M*. *smegmatis* methylfolate trap mutants, colonies of CDC1551 displayed a "white" morphology, differing from the yellow appearance of H37Rv, which resembles wild type *M*. *smegmatis* ([S6 Fig](#ppat.1005949.s006){ref-type="supplementary-material"}). To better understand the molecular mechanisms affecting trap formation, SULFA sensitivity tests were performed with a minimal medium (Dubos) and a gradient of increasing B~12~ concentrations ([Fig 3D](#ppat.1005949.g003){ref-type="fig"}). In the absence of exogenous B~12~, CDC1551 (numbered 2) displayed higher SULFA sensitivity compared to the CDC1551 strain *in trans* expressing the intact *metH* gene from H37Rv (CDC1551/*metH*, numbered 1), indicating that, unlike H37Rv, the B~12~ biosynthesis is functional in CDC1551 ([Fig 3D](#ppat.1005949.g003){ref-type="fig"}). The level of internally synthesized B~12~ was likely enough to partially repress the expression of *metE* and to activate MetH activity (see [Discussion](#sec010){ref-type="sec"}). When *cobIJ* was deleted (CDCΔ*cobIJ*/*metH* and CDCΔ*cobIJ*, numbered 3 and 4 respectively), SULFA resistance increased ([Fig 3D](#ppat.1005949.g003){ref-type="fig"}), possibly due to the derepression of *metE* in the complete absence of B~12~ (similar to H37Rv in minimal medium). Deletion of *bacA* (numbered 5 and 6), encoding the B~12~ uptake system in *M*. *tuberculosis* \[[@ppat.1005949.ref037]\], did not have any effect in this condition (far left panel). In the presence of as low as 0.25 μM B~12~, *metE* expression appeared to be further suppressed, making CDC1551 highly susceptible to SMZ compared to CDC1551/*metH* ([Fig 3D](#ppat.1005949.g003){ref-type="fig"}, second panel from left). The higher the concentration of exogenous B~12~, the less SULFA resistance was displayed by CDCΔ*cobIJ*, most likely due to increased suppression of *metE*. This was not seen in the case of CDCΔ*cobIJ*/*metH* since MetH was further activated in the presence of B~12~, thus compensating for *metE* suppression. Unlike CDC1551, CDCΔ*bacA* did not show a severe reduction in SULFA resistance when B~12~ was added due to its lack of B~12~ uptake activity. Similarly, but conversely, CDCΔ*bacA*/*metH* did not show an increased SULFA resistance compared to CDC1551/*metH* in response to exogenous B~12~. Most importantly, as seen with the H37Rv background ([Fig 3A](#ppat.1005949.g003){ref-type="fig"}), exogenous methionine did not enhance the SULFA resistance of CDC1551-derived strains ([Fig 3D](#ppat.1005949.g003){ref-type="fig"}).

Previous studies suggested that *M*. *tuberculosis* is able to uptake and metabolize B~12~ from its host \[[@ppat.1005949.ref041]\]. To evaluate if the methylfolate trap can form thus affecting the SULFA sensitivity of *M*. *tuberculosis* residing within macrophages, strains were used to infect the macrophage cell line J774.A1, grown in a medium containing 10% fetal bovine serum. The infected macrophages were treated with SMZ, followed by serial plating of the intracellular bacteria and c.f.u. counting. In both the H37Rv ([Fig 3E](#ppat.1005949.g003){ref-type="fig"}) and the CDC1551 backgrounds ([Fig 3F](#ppat.1005949.g003){ref-type="fig"}), strains lacking *metH* exhibited significantly increased sensitivity to SULFA treatment. *In trans* expression of H37Rv *metH* (*rv2124c*) restored SULFA resistance to both RvΔ*metH* and CDC1551 ([Fig 3E and 3F](#ppat.1005949.g003){ref-type="fig"}). As previously suggested \[[@ppat.1005949.ref039]\], the proliferation of CDC1551 in macrophages in the absence of SMZ was much faster compared to H37Rv ([Fig 3F](#ppat.1005949.g003){ref-type="fig"}). However, its survival was more severely reduced compared to H37Rv when the infected macrophages were treated with SMZ ([Fig 3F](#ppat.1005949.g003){ref-type="fig"}). This enhanced bactericidal activity of SMZ against CDC1551 was reduced in CDC1551/*metH*, confirming the correlation of MetH activity and the intrinsic resistance of CDC1551 to SULFAs.

Together, these results demonstrated that (*i*) the methylfolate trap, when successfully formed, can sensitize *M*. *tuberculosis* to SULFAs both *in vitro* and during infection of host macrophages, (*ii*) the methylfolate trap promotes the bactericidal activity of SULFA drugs, (*iii*) because of its non-functional B~12~ biosynthetic pathway, H37Rv relies on its uptake system to obtain exogenous B~12~, (*iv*) trace amounts of B~12~ are sufficient to suppress *metE* expression giving *metH* a more important role in preventing methylfolate trap formation, and (*v*) because of its truncated *metH* gene, CDC1551 is intrinsically more susceptible to methylfolate trap formation, rendering it more sensitive to SULFAs both *in vitro* and during macrophage infection \[[@ppat.1005949.ref042]\] ([Fig 3D and 3F](#ppat.1005949.g003){ref-type="fig"}). Our laboratory is currently investigating how mutations in *metH* and genes involved in B~12~ biosynthesis affect SULFA sensitivity among *M*. *tuberculosis* clinical isolates.

Methylfolate trap in Gram-negative bacteria {#sec006}
-------------------------------------------

To assess if the methylfolate trap plays a similar role in SULFA sensitivity in Gram-negative bacteria, we investigated its role in a selected group of significant pathogens with distinct metabolic capacities.

Similar to the *M*. *tuberculosis* H37Rv strain, *E*. *coli* does not synthesize B~12~, instead it imports the vitamin via the transport system BtuBCED \[[@ppat.1005949.ref043], [@ppat.1005949.ref044]\]. Whereas mutations in *btuC*, *btuE*, and/or *btuD* partially reduce uptake, mutations in *btuB* completely abolish B~12~ transport \[[@ppat.1005949.ref045]\]. On a complex medium, an *E*. *coli* Δ*btuCED* (*b1711*, *b1710*, and *b1709*, respectively) triple mutant remained SULFA resistant, whereas Δ*metH* (*b4019*), Δ*btuB* (*b3966*), and a Δ*btuB*Δ*CED* quadruple mutant all became hypersusceptible ([Fig 4A](#ppat.1005949.g004){ref-type="fig"}, [Table 1](#ppat.1005949.t001){ref-type="table"}). In serial dilution-spot tests using 125 μg/ml SMZ, these mutants displayed \>10^4^ times increased susceptibility compared to wild type BW25113 ([Fig 4A](#ppat.1005949.g004){ref-type="fig"}). Exogenous B~12~ was unable to restore SMZ resistance in these mutants due to the absence of MetH or B~12~ transport activity ([Fig 4A](#ppat.1005949.g004){ref-type="fig"}). The increased SULFA sensitivity was verified by measuring minimal inhibitory concentrations (MIC, [Table 1](#ppat.1005949.t001){ref-type="table"}), which is defined as the lowest concentration of an antibiotic that inhibits the visible growth of bacteria. To demonstrate methylfolate trap formation at the metabolic level, *E*. *coli* cultures were treated with SMZ and total folate was immediately extracted and analyzed by LC-MS/MS \[[@ppat.1005949.ref012]\]. As shown in [Fig 4B](#ppat.1005949.g004){ref-type="fig"}, 5-CH~3~-H~4~PteGlu~n~ markedly accumulated in Δ*metH* and Δ*btuB* compared to the parental strain, confirming methylfolate trap formation. Because of its inability to synthesize B~12~ *de novo*, *E*. *coli* relies entirely on import to prevent the methylfolate trap.

![Methylfolate trap and its role in Gram-negative bacteria.\
(**A**) SULFA susceptibility in *Escherichia coli* strains was analyzed by 10-fold serial dilutions. 5 μl of 10X diluted cell suspensions starting from OD1 were spotted on LB agar in the absence or presence of 125 μg/ml SMZ. Exogenous B~12~ was added at 2 nM final concentration. Growth was recorded after 48 h of incubation at 37°C. (**B**) Effect of *metH* and *btuB* on the folate pool of *E*. *coli*. Growing cultures (OD1) of *E*. *coli* strains were treated with 2.5 mg/ml SMZ for 15 min followed by folate extraction and LC-MS/MS analysis. Data shown, from top to bottom, are the combined levels of all 5-CH~3~-H~4~PteGlu~n~ species, all non-methylated folate species, and the total folate, respectively. Bars represent means of biological triplicates with standard deviations. ns, no significant difference between the indicated mutant and wild type *E*. *coli*. (**C**) Role of the methylfolate trap in SULFA sensitivity of *Pseudomonas aeruginosa* strains. Cultures underwent 10-fold serial dilutions, and 5 μl of diluted cultures were spotted onto solid media in the absence or presence of 150 μg/ml SMZ. Exogenous B~12~ was added at 2 nM final concentration. Growth was recorded after 48 h of incubation at 37°C. (**D**) Effect of *metH*, *btuB* and *cobI* on the folate pool of *P*. *aeruginosa*. Growing cultures (OD1) of *P*. *aeruginosa* strains were treated with 2.5 mg/ml SMZ for 15 min followed by folate extraction and LC-MS/MS analysis. Data shown, from top to bottom, are the combined levels of mono- and di-glutamylated methyl folate species (5-CH~3~-H~4~PteGlu~1-2~), tri- and tetra-glutamylated methyl folate species (5-CH~3~-H~4~PteGlu~3-4~), all non-methylated folate species, and the total folate. Bars represent means of biological triplicates with standard deviations. ns, no significant difference between the indicated mutant and wild type *P*. *aeruginosa*.](ppat.1005949.g004){#ppat.1005949.g004}

*P*. *aeruginosa* is capable of not only synthesizing *de novo* but also importing B~12~ from the environment. Transposon mutants with insertions in genes encoding *metH* (PA1843), *cobI* (PA2904), *cobJ* (PA2903), *cobH* (PA2905) and *btuB* (PA1271) were obtained from the Pseudomonas Transposon Mutant Collection (Manoil Laboratory, University of Washington Genome Sciences) \[[@ppat.1005949.ref046]\] ([S2 Table](#ppat.1005949.s013){ref-type="supplementary-material"}). The mutants were subjected to antifolate susceptibility tests, followed by folate analysis as described above. All *P*. *aeruginosa* mutants became more susceptible to SULFA drugs on a complex medium ([Fig 4C](#ppat.1005949.g004){ref-type="fig"}, [Table 1](#ppat.1005949.t001){ref-type="table"}). The *P*. *aeruginosa metH* and *btuB* mutants displayed identical, and the most severe susceptibility to SULFAs. These strains were at least 10^5^ times more susceptible than wild type as revealed by serial dilution-spotting assays using 125 μg/ml SMZ ([Fig 4C](#ppat.1005949.g004){ref-type="fig"}). *cob* mutants were less susceptible compared to these two strains, suggesting that B~12~ import is more important than *de novo* synthesis in the condition tested ([Fig 4C](#ppat.1005949.g004){ref-type="fig"}, [Table 1](#ppat.1005949.t001){ref-type="table"}). Indeed, exogenous B~12~ reinstated growth of the *cob* mutants but failed to do the same for *metH* and *btuB* ([Fig 4C](#ppat.1005949.g004){ref-type="fig"}). Chemical analyses also revealed accumulation of the methylfolate trap marker, 5-CH~3~-H~4~PteGlu~n~, in both *metH* and *btuB* ([Fig 4D](#ppat.1005949.g004){ref-type="fig"}).

Similar experiments with *S*. *typhimurium* strains (John Roth Laboratory, UC Davis, [S2 Table](#ppat.1005949.s013){ref-type="supplementary-material"}) confirmed the correlation of the methylfolate trap and increased SULFA susceptibility in bacteria ([Table 1](#ppat.1005949.t001){ref-type="table"}, [S7 Fig](#ppat.1005949.s007){ref-type="supplementary-material"}, and further studies below).

Dynamics of folate and related metabolites during methylfolate trap formation {#sec007}
-----------------------------------------------------------------------------

Similar to *M*. *smegmatis* and other Gram-negative bacteria, the deletion of *metH*, but not *metE*, resulted in the methylfolate trap and reduced SULFA resistance in *S*. *typhimurium* on complex media ([S7 Fig](#ppat.1005949.s007){ref-type="supplementary-material"}). The absence of *metH*, hence the methylfolate trap, led to increased susceptibility to SULFA drugs classified in all categories ([Fig 5A](#ppat.1005949.g005){ref-type="fig"}), but not to folate-unrelated antibiotics ([S8 Fig](#ppat.1005949.s008){ref-type="supplementary-material"}). To investigate if the effect of the methylfolate trap was bactericidal or bacteriostatic, *S*. *typhimurium metH*(+) and *metH*(-) strains were spotted on filters (\~10^4^ cells/filter), which were placed on the surface of Luria-Bertani (LB) agar plates supplemented with or without SMZ. Following 24 h of incubation at 37°C, cells from the inoculated filters were resuspended, and colony forming units (c.f.u.) were measured by serial dilution and plating. On LB agar free of SULFA, both *metH*(+) and *metH*(-) proliferated to 10^6^ times more cells than the input ([Fig 5B](#ppat.1005949.g005){ref-type="fig"}). In the presence of 125 μg/ml SMZ, growth of *metH*(+) was normal whereas only 0--8.5% of the *metH*(-) input survived ([Fig 5B](#ppat.1005949.g005){ref-type="fig"}), indicating an enhanced bactericidal effect of SMZ due to the methylfolate trap. In liquid LB, addition of 2.5 mg/ml SMZ similarly reduced growth of *metH*(-) while still allowing growth of *metH*(+) ([Fig 5C](#ppat.1005949.g005){ref-type="fig"}), confirming the correlation between SULFA resistance and MetH activity.

![Metabolic dynamics of the methylfolate trap in *Salmonella typhimurium* SULFA resistance.\
(**A**) Wide-spectrum SULFA susceptibility of *S*. *typhimurium metH*(+) and *metH*(-) analyzed by 10X serial dilution. Cultures were diluted starting with OD1 and 5 μl cell suspensions were spotted onto LB agar in the absence (control) or presence of different SULFAs, used at the indicated concentrations. These SULFA drugs are classified into all four subgroups, in left-right order: short-acting (blue), intermediate-acting (yellow), long-acting (green), and ultra-long-acting (pink), respectively. Growth was recorded after 48 h at 37°C. (**B**) Viability of *S*. *typhimurium metH*(+) (red) and *metH*(-) (blue) on LB agar 24 h post-SMZ addition (125 μg/ml). Colony forming units (c.f.u.) were determined and normalized to c.f.u. values of the inoculation input (0 h). The y-axis represents c.f.u. fold-change on a log10 scale of SMZ-treated (+SMZ, hatched bars) and control non-treated samples (-SMZ, empty bars). Error bars represent standard deviations from biological triplicates. \*\*\*\* p\<0.0001; ns, no significant difference. (**C**) SULFA susceptibility of *S*. *typhimurium* strains in liquid LB medium. Cultures of *metH*(+) (red) and *metH*(-) (blue) growing at OD1 was added with 2.5 mg/ml SMZ (arrow). Growth was monitored by measuring OD~600~. (**D**) Dynamics of the folate pool in *S*. *typhimurium metH*(+) (red) and *metH*(-) (blue) strains. At selected time points following SULFA treatment, cells were collected and folate extracted and analyzed by LC-MS/MS. Bars represent the combined levels of all 5-CH~3~-H~4~PteGlu~n~ species (top), all non-methylated folate species (middle), and total folate (bottom) following SMZ addition. s, significant difference between *metH*(-) and corresponding *metH*(+) samples; ns, no significant difference. (**E**) Dynamics of 41 metabolites in *metH*(+) (upper) and *metH*(-) (lower) strains. Metabolites are shown with their fold change over time (0--8 hours post SMZ addition). At selected time points following SMZ treatment, cells were collected and metabolites extracted and analyzed by LC-MS/MS. Signal intensity was normalized to OD~600nm~ at each time point. Relative levels are expressed as the log ratio of the normalized signal intensity of SMZ-treated cells at each time point to the normalized signal intensity of the no drug control sample at t = 0 (n = 3).\
The data shown in all figures represents the mean of biological repeats (n ≥ 3) with standard deviations. In the experiments demonstrated in [Fig 5C--5E](#ppat.1005949.g005){ref-type="fig"}, SMZ was added at 2.5 mg/ml when cultures reached OD1.](ppat.1005949.g005){#ppat.1005949.g005}

To investigate if the increased susceptibility was due to enhanced import, the SULFA uptake of *S*. *typhimurium* strains was measured using radioactive SMZ. However, both *metH*(+) and *metH*(-) displayed identical uptake following the addition of SMZ to the medium ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panel A). We next examined the effect of the methylfolate trap on the synthesis of macromolecules (DNA, RNA and protein) during SULFA treatment. Cells of *metH*(+) or *metH*(-) bacteria, growing in the presence of SMZ, were labeled using \[^3^H\]-thymidine, \[^3^H\]-uracil, or \[^35^S\]-methionine, respectively. While DNA and protein synthesis were not affected by the methylfolate trap during SULFA treatment, RNA synthesis was significantly reduced in cells suffering the metabolic blockage ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panels B-D).

To assess changes in the folate pool during SULFA-induced methylfolate trap formation, *S*. *typhimurium* cells growing in liquid LB medium were treated with SMZ, followed by sample collection. Folate was extracted and individual species quantified using LC-MS/MS. In the presence of MetH, combined levels of both methylated (5-CH~3~-H~4~PteGlu~n~) and non-methylated folate species (R-H~4~PteGlu~n~ R ≠ CH~3~) immediately and continuously declined in response to SMZ ([Fig 5D](#ppat.1005949.g005){ref-type="fig"}, top and middle panels, red bars; see also [S10 Fig](#ppat.1005949.s010){ref-type="supplementary-material"} for the dynamics of individual species). In contrast, in *metH*(-) cells, 5-CH~3~-H~4~PteGlu~n~ gradually accumulated following SMZ treatment ([Fig 5D](#ppat.1005949.g005){ref-type="fig"}, top panel, blue bars). Levels of non-methylated folate species in *metH*(-) gradually declined for the first hour, then remained constant for the remainder of the experiment ([Fig 5D](#ppat.1005949.g005){ref-type="fig"}, middle panel, blue bars). This result indicated possible cellular feedback, either through an increase in *de novo* H~4~PteGlu~n~ synthesis or rearrangement in the inter-conversion network of one-carbon metabolism.

To further analyze metabolic alterations in response to such folate homeostatic defects, post-SMZ treatment levels of 41 metabolites were profiled using LC-MS/MS-based metabolomics. Cells were sampled from growth curves similar to those in [Fig 5C](#ppat.1005949.g005){ref-type="fig"} from which metabolites were extracted and analyzed by the Metabolomics Lab at the Roy J. Carver Biotechnology Center (University of Illinois at Urbana-Champaign). Metabolic abnormalities caused by the SMZ-induced methylfolate trap include the accumulation of intermediates within the methionine-homocysteine cycle (Figs [5E](#ppat.1005949.g005){ref-type="fig"} and [6A](#ppat.1005949.g006){ref-type="fig"}, orange), glycine (Figs [5E](#ppat.1005949.g005){ref-type="fig"} and [6B](#ppat.1005949.g006){ref-type="fig"}, red) and nucleotides (Figs [5E](#ppat.1005949.g005){ref-type="fig"} and [6C](#ppat.1005949.g006){ref-type="fig"}, purple), as discussed in more detail below.

![Methylfolate trap-mediated thymineless death.\
(**A**) Cellular levels of methionine, SAM, and SAH in *S*. *typhimurium* cells following SMZ treatment. *metH*(-) (blue triangle) displayed a lower level of methionine but higher levels of SAM and SAH than its parent *metH*(+) (red circle). (**B**) Higher level of glycine in *metH*(-) (blue triangle) compared to *metH*(+) (red circle). (**C**) Dynamics of nucleotide pool in *S*. *typhimurium* cells during SMZ treatment. While the levels of nucleotides and intermediates were sharply reduced in response to SMZ in *metH*(+) (red circle), cells of *metH*(-) (blue triangle) failed to deplete these metabolites. (**D**) Thymine abolishes SULFA-induced cell death and restores growth in *metH*(-). *Salmonella* cultures were 10X serially diluted and 5 μl of diluted cultures were spotted on LB agar in the absence or presence of 125 μg/ml SMZ and 2 mM thymine. Growth on test plates (top panel) was recorded after 24 h of incubation at 37°C. Corresponding 24-hour viability of colonies grown from spotted OD0.001 cell suspensions (arrow) was determined by measuring c.f.u. and normalized to c.f.u. values of the input inoculum (lower panel). The y-axis represents c.f.u. fold-change on a log10 scale. Bars represent standard deviations from biological triplicates. \*\*\* p\<0.001; \*\*\*\* p\<0.0001.](ppat.1005949.g006){#ppat.1005949.g006}

Thymineless death caused by the methylfolate trap {#sec008}
-------------------------------------------------

The MetH reaction connects the one-carbon metabolic network with the methionine cycle through its conversion (methylation) of Hcy to methionine ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panel E). Therefore, impaired MetH would lead to the accumulation of not only 5-CH~3~-H~4~PteGlu~n~, but also Hcy, causing hyperhomocysteinemia. In the cell, Hcy is further converted to Hcy-thiolactone, which is cytotoxic due to its interaction with physiologically important proteins \[[@ppat.1005949.ref047], [@ppat.1005949.ref048]\]. Because it is neutral at physiological pH (pKa = 6.67), Hcy-thiolactone is steadily secreted into exogenous media following its production from Hcy \[[@ppat.1005949.ref048]\]. Besides harvesting cells for folate and metabolomic analyses ([Fig 5D and 5E](#ppat.1005949.g005){ref-type="fig"}), culture filtrates from *metH*(+) and *metH*(-) growing in the presence of SMZ were also collected for Hcy-thiolactone analysis ([S1 Text](#ppat.1005949.s016){ref-type="supplementary-material"}) \[[@ppat.1005949.ref049]\]. As shown in [Fig 6A](#ppat.1005949.g006){ref-type="fig"}, cells of *metH*(-) accumulated *S*-adenosylhomocysteine (SAH), which led to higher levels of Hcy-thiolactone in the medium compared to *metH*(+) ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panel F).

In the presence of MetH (red circle), production of methionine ([Fig 6A](#ppat.1005949.g006){ref-type="fig"}) and glycine ([Fig 6B](#ppat.1005949.g006){ref-type="fig"}) rapidly dropped while levels of nucleotides ([Fig 6C](#ppat.1005949.g006){ref-type="fig"}) including aminoimidazole carboxamide ribonucleotide (AICAR), a precursor of purine synthesis, slightly increased during the first half an hour to one hour of SMZ treatment. Thereafter, synthesis of methionine and glycine resumed but nucleotides underwent continuous depletion. In the absence of MetH (blue triangle), methionine synthesis slightly increased ([Fig 6A](#ppat.1005949.g006){ref-type="fig"}), most likely due to increased uptake, nucleotides levels also increased ([Fig 6C](#ppat.1005949.g006){ref-type="fig"}), but glycine levels slightly declined ([Fig 6B](#ppat.1005949.g006){ref-type="fig"}) in the first hour. After this time period, nucleotides, especially dUMP, remained highly elevated, methionine levels declined and remained constant while glycine levels increased and remained elevated.

Antifolate-responsive depletion of intracellular glycine and purines was recently proposed as an *E*. *coli* mechanism to escape thymineless death \[[@ppat.1005949.ref015]\]. To test if thymine plays a role in the methylfolate trap-promoted bactericidal activity of SULFA, this nucleotide precursor was added to medium and the survival of strains was evaluated by serial dilution and plating method. Interestingly, thymine abolished the SULFA-induced death of the *metH*(-) strain, and restored its growth ([Fig 6D](#ppat.1005949.g006){ref-type="fig"}). These results suggest that the methylfolate trap promotes the intrinsic thymineless death of bacteria by SULFA drugs, by causing an imbalance in nucleotide levels while preventing cellular depletion of glycine.

Methylfolate trap-mediated SULFA sensitization in a monocyte infection model {#sec009}
----------------------------------------------------------------------------

To investigate if the methylfolate trap renders bacteria more susceptible to SULFAs in a host cell environment, we first monitored the intracellular survival of *S*. *typhimurium* strains in J774A.1, a macrophage cell line commonly used for antibiotic sensitivity testing \[[@ppat.1005949.ref050]\]. When the infected macrophages were treated with SMZ at a concentration sub-inhibitory for the *S*. *typhimurium* parental strain, mutants undergoing the methylfolate trap displayed significant defects in survival ([Fig 7A](#ppat.1005949.g007){ref-type="fig"}). The survival of the *S*. *typhimurium* strains in macrophages resembled the patterns of *in vitro* sensitivity ([S7 Fig](#ppat.1005949.s007){ref-type="supplementary-material"}), suggesting a similar role of the methylfolate trap in promoting SULFA susceptibility of intracellular bacteria.

![Genetic and chemical induction of the methylfolate trap during *Salmonella* infection of macrophages.\
(**A**) Survival of *Salmonella* strains in macrophages treated with SULFAs. Macrophages J774A.1 were infected for 1 h followed by 18 h chase, during which cells were untreated or treated with 1 mg/ml SMZ. Colony forming units (c.f.u.) were determined by serial dilution and plating method. (**B**) Cellular uptake and conversion of exogenous B~12~ in mammalian cells requires transcobalamin (TC) and CblC proteins, respectively. Antivitamin B~12~ molecules such as EtPhCbl inhibit transcobalamin and CblC, thereby restricting B~12~ bioavailability to intracellular bacteria. (**C**) Depletion of CblC expression, detected by Western Blot using a specific antibody (top), caused B~12~ starvation (middle) and increased SULFA sensitivity (bottom) of intracellular *Salmonella*. siRNA transfected THP-1 macrophages were infected with *S*. *typhimurium* cells expressing β-galactosidase from a B~12~ starvation-responsive promoter for 1 h, followed by 18 h chase, during which the infected macrophages were treated without or with 1 mg/ml SMZ. B~12~ starvation was estimated by determining β-galactosidase activity while *Salmonella* survival measured by c.f.u. counting. (**D**) Chemical restriction of B~12~ sensitizes intracellular *S*. *typhimurium* to SULFA treatment. Macrophages J774A.1 were infected with *S*. *typhimurium* cells harboring a B~12~ molecular probe for 1 h followed by 18 h chase, during which cells were untreated or treated with 1 mg/ml SMZ or/and 50 nM EtPhCbl. B~12~ starvation was estimated through measuring enzymatic activity (top) and expression of β-galactosidase by Western Blot (middle). *Salmonella* survival from the corresponding macrophages was measured through c.f.u. counting (bottom). Error bars represent standard deviations from biological triplicates. ns, no significant difference compared to control groups.](ppat.1005949.g007){#ppat.1005949.g007}

To assess if SULFA susceptibility of the intracellular bacteria can be promoted through pharmacological induction of the methylfolate trap, we sought to restrict B~12~ bioavailability using a chemical approach ([Fig 7B](#ppat.1005949.g007){ref-type="fig"}). The cellular uptake and conversion of exogenous B~12~ (cyanocobalamin) to biologically active cofactors (adenosylcobalamin and methylcobalamin) in mammalian cells requires the enzymatic activity of CblC, also known as MMACHC (for methylmalonic aciduria (cobalamin deficiency) *cblC* type, with homocystinuria) \[[@ppat.1005949.ref051]\]. To investigate if B~12~ bioavailability, hence SULFA sensitivity, of intracellular *S*. *typhimurium* could be controlled through CblC inhibition, expression of *cblC* in macrophages THP-1 was depleted using RNA interference. Transfection with *cblC*-specific siRNA effectively reduced CblC expression, detected by Western Blot using a CblC monoclonal antibody ([Fig 7C](#ppat.1005949.g007){ref-type="fig"}, top panel). The reduced *cblC* expression was found to correlate with increased B~12~ starvation of the intracellular *S*. *typhimurium* bacillus as detected by a B~12~ molecular probe ([Fig 7C](#ppat.1005949.g007){ref-type="fig"}, middle) \[[@ppat.1005949.ref052]\]. Within such CblC-depleted macrophages, *S*. *typhimurium* became more SMZ susceptible as determined by c.f.u plating assays ([Fig 7C](#ppat.1005949.g007){ref-type="fig"}, bottom).

We recently developed Co~β~-4-ethylphenylcob-(III)alamin (EtPhCbl) \[[@ppat.1005949.ref053]\], a cobalamin analog that can function as a vitamin B~12~ antagonist (or "antivitamin B~12~") \[[@ppat.1005949.ref053], [@ppat.1005949.ref054]\]. EtPhCbl effectively binds to CblC but resists dissociation from the protein, thereby blocking CblC from its normal functions of decyanation and dealkylation of newly internalized cyanocobalamin and methylcobalamin, respectively \[[@ppat.1005949.ref055], [@ppat.1005949.ref056]\]. Because bacteria do not have CblC homologs, EtPhCbl had no effect when used directly on bacterial cells ([S11 Fig](#ppat.1005949.s011){ref-type="supplementary-material"}). To test whether EtPhCbl increases methylfolate trap-mediated SULFA susceptibility in bacteria residing within host cells, macrophages were first infected with *S*. *typhimurium*. Thereafter, the infected cells were treated with SMZ, EtPhCbl, or their combination. Cells were then lysed and intracellular bacteria determined by c.f.u. plating assays. Whereas SMZ or EtPhCbl alone did not affect the intracellular survival of *S*. *typhimurium*, their combination resulted in both B~12~ starvation ([Fig 7D](#ppat.1005949.g007){ref-type="fig"}, top and middle), and a significant c.f.u. reduction ([Fig 7D](#ppat.1005949.g007){ref-type="fig"}, bottom) to the intracellular bacillus.

Discussion {#sec010}
==========

We first constructed a large library of transposon insertion mutants in *M*. *smegmatis*. The size of the library was approximately 2 times the number of genes in the *M*. *smegmatis* genome (6,717 protein-coding genes and 54 RNA-coding genes, <http://www.genome.jp/kegg-bin/show_organism?org=msm>). Screening this library, we identified 50 chromosomal loci responsible for the intrinsic antifolate resistance in *M*. *smegmatis* ([S1 Table](#ppat.1005949.s012){ref-type="supplementary-material"}). Further investigation of the inserted genes revealed many novel pathways previously unknown to be involved in bacterial intrinsic antifolate resistance. For example, we recently reported the role of 5,10-methenyltetrahydrofolate synthase (MTHFS, encoded by *msmeg_5472*), which converts 5-CHO-H~4~PteGlu~n~, a proposed storage form of folate, to 5,10-CH^+^-H~4~PteGlu~n~, in cellular folate homeostasis and bacterial antifolate resistance \[[@ppat.1005949.ref012]\]. These studies, including the current work reported in this paper, confirm the richness of potential drug targets in this pathway as previously postulated \[[@ppat.1005949.ref057], [@ppat.1005949.ref058]\]. The fact that many loci were repeatedly identified in the screen confirmed the saturation of the library. It is however important to note that our screening procedures only selected mutants that showed "normal growth" in the absence of antifolates; thus resistance determinants encoded by essential genes or genes whose mutation affected *M*. *smegmatis* growth on NE medium in the absence of antifolates were not included in this pool.

In further studies of the mutant library, we have now discovered another novel mechanism of intrinsic SULFA resistance in bacteria referred to as the methylfolate trap, which occurs when cellular H~4~PteGlu~n~ is trapped in a single methylated form, 5-CH~3~-H~4~PteGlu~n~ \[[@ppat.1005949.ref021], [@ppat.1005949.ref059]\]. We show that the methylfolate trap increases the bactericidal activity of SULFA drugs against mycobacteria and Gram-negative bacteria. The methylfolate trap hypothesis was first proposed by Herbert and Zalusky in 1962 to explain the cause of megaloblastic anemia observed in patients deficient in folate and vitamin B~12~ \[[@ppat.1005949.ref019]\]. Besides the typical low blood count and macrocytosis, cells from those patients encountered a "pseudo-folate deficient" state, in which folic acid injected into tissues rapidly disappeared while 5-CH~3~-H~4~PteGlu~n~ "piled up" in sera. However, simultaneous treatment of many of those patients with vitamin B~12~ immediately corrected the folate leakage and blood count normalized \[[@ppat.1005949.ref020], [@ppat.1005949.ref059], [@ppat.1005949.ref060]\]. These phenomena were hypothesized to be a result of deficiencies in the B~12~-dependent methionine synthase (MetH) activity, which converts 5-CH~3~-H~4~PteGlu~n~ and Hcy to H~4~PteGlu~n~ and methionine, respectively. This hypothesis was supported by the fact that all patients with inborn genetic errors in the *metH* gene suffer from anemia or developmental delay; and exhibit accumulation of 5-CH~3~-H~4~PteGlu~n~ and Hcy \[[@ppat.1005949.ref061], [@ppat.1005949.ref062]\]. However, direct genetic evidence connecting *metH* and the methylfolate trap has not been established because constructing *metH* knockout mice has proved unsuccessful thus far \[[@ppat.1005949.ref027]\]. Nonetheless, the methylfolate trap hypothesis is now widely accepted to explain the relationships of B~12~, folate, and Hcy homeostasis in many human diseases \[[@ppat.1005949.ref063]\].

The methylfolate trap and its physiological consequences have never been described in bacteria, plants or microbial eukaryotes, possibly because these organisms are able to synthesize folate *de novo*, thus minimizing the trap's effects. Interestingly, our data show that the methylfolate trap is lethal to bacteria when it is formed in the presence of SULFA drugs, which inhibit *de novo* folate biosynthesis. Due to the lack of *de novo* folate synthesis, mammalian cells undergoing the methylfolate trap exhibit a depletion of non-methyl folate species, consequently leading to reduced synthesis of amino acids and nucleotides from the one-carbon metabolic network. By contrast, the levels of non-methyl folate species in bacterial cells experiencing the trap only modestly reduced or did not change, while total folate elevated because of the increase in 5-CH~3~-H~4~PteGlu~n~ levels (Figs [2C](#ppat.1005949.g002){ref-type="fig"}, [4B, 4D](#ppat.1005949.g004){ref-type="fig"} and [5D](#ppat.1005949.g005){ref-type="fig"}). This was most likely due to an increase in *de novo* folate synthesis in response to the continuous loss of folate molecules trapped in the irreversible 5-CH~3~-H~4~PteGlu~n~ form. Such a response leads to two possible lethal consequences: (*i*) a wasteful cycle of synthesis and loss of H~4~PteGlu~n~ which rapidly depletes cellular resources, or (*ii*) an uncoordinated increase in activity of the early steps preceding the MetH reaction in the one-carbon metabolic network ([Fig 1A](#ppat.1005949.g001){ref-type="fig"}). Because thymidylate synthase is a rate-limiting reaction, such an increase in H~4~PteGlu~n~ influx in the absence of MetH would lead to increased synthesis of some amino acids and nucleotides while levels of thymidine nucleotides remain low, thus promoting "unbalanced" growth that causes thymineless death \[[@ppat.1005949.ref013]\]. Our metabolomic data shed light on these possibilities. Besides the extracellular accumulation of Hcy-thiolactone ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panel F), which may be deleterious to exogenously functioning molecules, cells undergoing the methylfolate trap were unable to deplete glycine and nucleotides ([Fig 6B and 6C](#ppat.1005949.g006){ref-type="fig"}). Cellular depletion of glycine and purines was found necessary for bacterial escape from thymineless death, a known contributor to the bactericidal activity of antifolates \[[@ppat.1005949.ref015], [@ppat.1005949.ref016]\]. Although thymidine triphosphate (dTTP) was not detectable in cells subjected to our experimental conditions, the level of deoxyuridine monophosphate (dUMP), a precursor of dTTP, increased 700 fold in the absence of MetH after 8 hours of SMZ treatment ([Fig 6C](#ppat.1005949.g006){ref-type="fig"}, 219.26 in *metH*(-) versus 0.31 in *metH*(+), p = 0.0371), indicating low activities of thymidylate synthase (TS, [Fig 1A](#ppat.1005949.g001){ref-type="fig"}) in the presence of the methylfolate trap. Cellular accumulation of dUMP, leading to robust dUTP production, has been known to contribute to thymineless death by causing misincorporation of uracil into DNA \[[@ppat.1005949.ref064]\]. Importantly, exogenous supplementation of thymine completely abolished the SULFA-induced death in *metH*(-) ([Fig 6D](#ppat.1005949.g006){ref-type="fig"}). In addition, cells suffering the methylfolate trap displayed unchanged synthesis of proteins and DNA but reduced synthesis of RNA ([S9 Fig](#ppat.1005949.s009){ref-type="supplementary-material"}, panel C), a hallmark exhibited by bacterial cells that undergo thymineless death \[[@ppat.1005949.ref065], [@ppat.1005949.ref066]\]. Together, our studies suggest that the methylfolate trap boosts the bactericidal activity of SULFAs by inducing thymineless death.

It is important to note that many bacteria also encode MetE, a B~12~-independent methionine synthase \[[@ppat.1005949.ref035]\]. However, catalytic activity of MetE is more than a hundred fold lower than that of MetH \[[@ppat.1005949.ref067], [@ppat.1005949.ref068]\], and the expression of *metE* is sensitive to B~12~ exposure \[[@ppat.1005949.ref038]\], making MetH the dominant methionine synthase. In fact, our data indicated that neither deletion nor overexpression of *metE* affected SULFA susceptibility in *M*. *smegmatis* ([S4 Fig](#ppat.1005949.s004){ref-type="supplementary-material"} and [S5 Fig](#ppat.1005949.s005){ref-type="supplementary-material"}) and *S*. *typhimurium* ([S7 Fig](#ppat.1005949.s007){ref-type="supplementary-material"}), and that *de novo* synthesized B~12~ contributes to partially inhibiting *metE* expression in autotrophic bacteria. In the complete absence of exogenous B~12~ in minimal media, B~12~ auxotrophic bacteria such as the *M*. *tuberculosis* laboratory strain H37Rv are able to use MetE activity to prevent trap formation. However, exposure to minute amounts of B~12~ is enough to suppress *metE* expression. With previous studies showing that functionally adequate levels of B~12~ are accessible to bacterial pathogens during vertebrate host infections \[[@ppat.1005949.ref041]\], the role of MetE in the methylfolate trap-mediated SULFA sensitization is likely negligible. The fact that *metH* deletion leads to increased SULFA sensitivity in H37Rv during macrophage infection ([Fig 3E](#ppat.1005949.g003){ref-type="fig"}) further suggested that this bacterium is able to acquire B~12~ from the host cell, and that the acquired B~12~ is sufficient for preventing methylfolate trap formation.

Similar to mammalian cells, bacteria undergoing restricted *de novo* folate synthesis caused by SULFAs relied on vitamin B~12~ for preventing methylfolate trap formation. Accordingly, reduced B~12~ bioavailability could sensitize some bacterial pathogens to SULFAs. Our experiments presented in [Fig 7](#ppat.1005949.g007){ref-type="fig"} provide a proof-of-concept that this folate antagonistic strategy, namely the chemical promotion of the methylfolate trap, is feasible for inducing the killing of pathogenic bacteria by SULFAs. However, targeting B~12~ bioavailability by general antivitamin B~12~ molecules may not be effective for some bacteria, providing the heterogeneity of B~12~ biosynthesis and uptake. In addition, it is currently not known if such antivitamin B~12~ compounds play a role in the regulation of B~12~ synthesis or uptake in the targeted bacterial pathogens. Another challenge is how to develop methylfolate trap inducers that are specific for bacteria, thus causing no significant toxicity to mammalian cells. In this regard, targeting bacterial proteins involved in B~12~ uptake and salvage, which are distinct from those of the mammalian counterparts, may provide a possible strategy. As we have previously proposed \[[@ppat.1005949.ref012], [@ppat.1005949.ref057], [@ppat.1005949.ref058]\], antifolate resistance determinants such as the methylfolate trap represent potential targets for the development of SULFA boosters, which not only protect the efficacy of SULFAs but also increase their potency against drug resistant pathogens. With the increasing use of co-trimoxazole (SMZ plus TMP) in prophylactic treatments of HIV positive patients throughout the world \[[@ppat.1005949.ref010]\], such SULFA boosters are urgently needed.

Materials and Methods {#sec011}
=====================

Bacterial strains, plasmids, primers, and growth media {#sec012}
------------------------------------------------------

Strains, plasmids, and primers used in this study are listed in [S2](#ppat.1005949.s013){ref-type="supplementary-material"}, [S3](#ppat.1005949.s014){ref-type="supplementary-material"} and [S4](#ppat.1005949.s015){ref-type="supplementary-material"} Tables of the Supporting Information, which also contain information on the genetic screen and identification of antifolate-sensitive mutants, targeted gene deletion, genetic and chemical complementation, extraction and analysis of cellular folate derivatives, and antibiotic susceptibility tests ([S1 Text](#ppat.1005949.s016){ref-type="supplementary-material"}). *M*. *smegmatis* mc^2^155 and its derived transposon mutants were grown in LB broth or 7H9 (Difco) supplemented with glucose and 0.5% Tween 80. *M*. *tuberculosis* strains were grown in 7H10-OADC or Dubos-ADC media (Difco). Unless otherwise stated, Gram-negative bacteria were grown in LB broth or LB agar.

Statistical analysis {#sec013}
--------------------

Statistical analyses were conducted using GraphPad Prism 5.0f software (La Jolla, CA). Students two-tailed *t*-test was used to analyze the statistical significance of differences between groups.

Addition methods {#sec014}
----------------

Other methods used in this study can be found in the Supporting Information ([S1 Text](#ppat.1005949.s016){ref-type="supplementary-material"}).

Supporting Information {#sec015}
======================

###### *Himar1* insertions and MetH truncation mutants in *M*. *smegmatis*.

(**A**) *Himar1* insertion into the *metH* (*msmeg_4185*) gene in 124H4, 63H1, 121D7 and 58B10. Arrows indicate the positions of the TA dinucleotides where *Himar1* inserted. (**B**) Domain alignment of MetH truncation mutants compared to wild type using PROSITE ([http://prosite.expasy.org](http://prosite.expasy.org/)). The truncated proteins in 58B10 and 121D7 are similar to that of CDC1551 shown [Fig 3C](#ppat.1005949.g003){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Role of *metH* in *M*. *smegmatis* SULFA resistance.

A representative disc diffusion test shows the effect of *metH* deletion on *M*. *smegmatis* SULFA resistance. Cells of wild type (top left), *Ms*Δ*metH* (top right), and complemented strain (bottom right) were seeded onto the surface of NE medium. Discs containing SULFA drugs classified in different subgroups were applied at the positions indicated in the bottom left panel. Colors indicate the groups to which the antibiotics belong. Non-SULFA antifolates were included as controls.

(PDF)

###### 

Click here for additional data file.

###### Role of *metH* in *M*. *smegmatis* susceptibility to non-antifolates.

A representative disc diffusion test shows that *metH* is not involved in *M*. *smegmatis* resistance to non-antifolate drugs. Cells of wild type (top left) and *Ms*Δ*metH* (top right) were seeded onto the surface of NE. Antibiotic discs were applied at the positions indicated in the bottom left panel. Colors indicate the classification of the antibiotics tested (bottom right).

(PDF)

###### 

Click here for additional data file.

###### Role of *metE* in *M*. *smegmatis* SULFA resistance tested on rich media.

**(A**) SULFA susceptibility tested by 10X serial dilution on NE medium. Cultures growing at OD1 were 10X serially diluted, and 5 μl cell suspensions were spotted onto NE without (-) or with (+) 10.5 μg/ml SCP. Growth was recorded after 5 days of incubation at 37°C. (**B**) SULFA susceptibility tested by disc diffusion on NE medium. Cells of *M*. *smegmatis* strains were seeded onto the surface of NE plates and paper discs embedded with 1 mg SCP were placed at the center. Susceptibility, visualized as the zone of inhibition surrounding the discs, was recorded after 5 days of incubation at 37°C. Neither deletion nor overexpression of *metE* altered *M*. *smegmatis* SULFA resistance. Similar experiments performed on LB agar were demonstrated in figures (**C**) and (**D**), respectively.

(PDF)

###### 

Click here for additional data file.

###### Role of *metE* in *M*. *smegmatis* SULFA resistance tested on a minimal medium.

**(A**) SULFA susceptibility tested by 10X serial dilution on 7H10 medium. Cultures growing at OD1 were 10X serially diluted, and 5 μl cell suspensions were spotted onto 7H10 without (-) or with (+) 5 μg/ml SCP. Growth was recorded after 5 days of incubation at 37°C. (**B**) SULFA susceptibility tested by disc diffusion on 7H10 medium. Cells of *M*. *smegmatis* strains were seeded onto the surface of 7H10 plates and paper discs embedded with 1 mg SCP were placed at the center. Susceptibility, visualized as the zone of inhibition surrounding the discs, was recorded after 5 days of incubation at 37°C.

(PDF)

###### 

Click here for additional data file.

###### Morphological differences of *M*. *tuberculosis* strains.

Cells of H37Rv, CDC1551, and the CDC1551 strain *in trans* expressing the *metH* gene from H37Rv (CDC1551/*metH*), were inoculated on the surface of a solid rich medium (NE-OADC, top) or a minimal medium (7H10-OADC, bottom). Morphology was recorded after 2 and 4 weeks of growth at 37°C. Colonies of CDC1551 resembled the *M*. *smegmatis* "white" mutants while *in trans* expression of the *metH* gene from H37Rv results in a morphology similar to H37Rv.

(PDF)

###### 

Click here for additional data file.

###### SULFA susceptibility of *S*. *typhimurium* strains.

(**A**) SULFA susceptibility tested by 10X serial dilution. Cultures growing at OD1 were 10X serially diluted, and 5 μl cell suspensions were spotted on LB agar without (-) or with (+) 125 μg/ml SMZ. Growth was recorded after 48 h at 37°C. (**B**) Effects of methionine synthases and B~12~ related genes on the folate pool of *S*. *typhimurium* growing in the complex LB medium. Shown are cellular levels of methyl folate (top), non-methyl folate (middle) and total folate (bottom) in *S*. *typhimurium* strains treated with SMZ. Bars represent means of biological triplicates with standard deviations. ns, no significant difference compared to the parental strain.

(PDF)

###### 

Click here for additional data file.

###### Role of *metH* in *S*. *typhimurium* susceptibility to non-antifolates.

A representative disc diffusion test shows that *metH* does not affect *S*. *typhimurium* resistance to non-antifolates. Cells of *metH*(+) (top left) and *metH*(-) (top right) were seeded onto the surface of LB agar. Antibiotic discs were applied at positions indicated in the bottom left panel. Bottom right panel indicates the antibiotics' classification.

(PDF)

###### 

Click here for additional data file.

###### Additional characterization of the methylfolate trap in *S*. *typhimurium*.

(**A**) SULFA uptake by *S*. *typhimurium* strains. Cultures of *metH*(+) (red) and *metH*(-) (blue) were grown to OD1 when 1 μCi/ml \[^3^H\]-SMZ was added. At selected time points, samples were collected and cells were filtered and washed. Incorporated radioactivity was measured by liquid scintillation counting. Bars represent means of biological triplicates with standard deviations. ns, no significant difference. (**B-D**) Synthesis of DNA, RNA, and protein of *S*. *typhimurium metH*(+) (red) and *metH*(-) (blue) strains following SULFA treatment. 2.5 mg/ml SMZ was added when cultures reached OD1. At selected time points post-SMZ treatment, samples from each strain were collected and treated with 10 μCi/ml \[^3^H\]-thymidine (B), 10 μCi/ml \[^3^H\]-uracil (C), or 8 μCi/ml \[^35^S\]-methionine (D), respectively, for 20 min at 37°C. Following treatment with 1 M NaOH for 30 min at 50°C, macromolecules were precipitated with cold TCA, filtered onto Whatman glass microfibers, and washed. Incorporated radioactivity was measured by liquid scintillation counting. Bars represent means of biological triplicates with standard deviations. \*, significant differences in RNA synthesis between *metH*(+) and *metH*(-), p\<0.05; ns, no significant difference. (**E**) Diagram depicting the interaction of one-carbon metabolism and the methionine-homocysteine cycle. When the reaction catalyzed by B~12~-dependent methionine synthase fails, the methylfolate trap occurs, resulting in the accumulation of not only 5-CH~3~-H~4~PteGlun but also SAM and SAH. Besides the sulfate assimilation pathway, bacteria can convert SAH to Hcy, either directly or through the formation of *S*-ribosylhomocysteine (SRH). Hcy is further converted to Hcy-thiolactone (HTL), which interacts with selected proteins thus affecting their functions. (**F**) Extracellular accumulation of Hcy-thiolactone (HTL, μM) in *metH*(-) cultures (blue) compared to *metH*(+) (red) during growth in the presence of SULFAs. Cultures were collected following the addition of 2.5 mg/ml SMZ and cells were removed by centrifugation. Samples were separated by HPLC with fluorescence detection. Bars represent means of biological triplicates with standard deviations. Bars represent means of biological triplicates with standard deviations. \*\* p \< 0.01; \*\*\* p\< 0.001; ns, no significant difference.
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Click here for additional data file.

###### Dynamics of individual folate species in *S*. *typhimurium* strains.

Dynamics of individual folate species in *S*. *typhimurium metH*(+) (top) and *metH*(-) (bottom) cells following SULFA treatment. At selected time points following the addition of 2.5 mg/ml SMZ, cells were collected, and folate was extracted and analyzed by LC-MS/MS.
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Click here for additional data file.

###### Effect of EtPhCbl on *in vitro* SULFA susceptibility.

SULFA susceptibility in *E*. *coli*, *S*. *typhimurium*, *P*. *aeruginosa*, and *M*. *smegmatis* was analyzed by 10X serial dilution. 5 μl cell suspensions were spotted onto LB agar in the absence or presence of 125 μg/ml SMZ, and varying concentrations of B~12~ or EtPhCbl (antivitamin B~12~). Growth was recorded after 48 h at 37°C.
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Click here for additional data file.

###### Whole-genome antifolate resistance determinants in *M*. *smegmatis*.
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Click here for additional data file.

###### Strains used in this study.
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Click here for additional data file.

###### Plasmids used in this study.

(DOC)
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Click here for additional data file.

###### Oligonucleotides used in this study.

(DOC)
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Click here for additional data file.

###### Additional methods used in this study.

(DOC)

###### 

Click here for additional data file.
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